首页> 外国专利> ANTIBODIES OR FUSION PROTEINS MULTIMERIZED VIA CYSTEINE MUTATION AND A MU TAILPIECE

ANTIBODIES OR FUSION PROTEINS MULTIMERIZED VIA CYSTEINE MUTATION AND A MU TAILPIECE

机译:通过半胱氨酸突变和MU尾钉将抗体或融合蛋白多元化

摘要

The invention provides constant regions incorporating a cysteine mutation and linked to a μ tailpiece and antibodies or fusion proteins incorporating the same. The constant regions include at least CH2 and CH3 regions of an IgG heavy chain constant region including a cysteine mutation and μ tailpiece. Antibodies or fusion proteins incorporating the constant regions gains the ability to form multivalent complexes, e.g., pentameric or hexameric structures. Antibodies or fusion proteins incorporating the constant regions also retain IgG properties including specific binding to protein G, which facilitates purification and may exhibit pH-dependent FcRn binding, which is associated with a relatively long in vivo half-life. Depending on the isotype and subtype, the nature of the antigen and presence of an additional IgG hinge domain, such antibodies or fusion proteins may also have properties of specific binding to protein A, and effector functions such as ADCC, CDC and opsonization.
机译:本发明提供了掺入半胱氨酸突变并与μ尾巴连接的恒定区和掺入了该恒定区的抗体或融合蛋白。恒定区至少包括包含半胱氨酸突变和μ尾部的IgG重链恒定区的CH 2和CH 3区。掺入恒定区的抗体或融合蛋白具有形成多价复合物的能力,例如五聚体或六聚体结构。掺入恒定区的抗体或融合蛋白还保留IgG特性,包括与蛋白G的特异性结合,这有助于纯化,并可能表现出pH依赖性FcRn结合,这与较长的体内半衰期有关。根据同种型和亚型,抗原的性质和其他IgG铰链结构域的存在,此类抗体或融合蛋白还可能具有与蛋白A特异性结合的特性,以及效应子功能(如ADCC,CDC和调理作用)。

著录项

  • 公开/公告号EP2880057A4

    专利类型

  • 公开/公告日2016-03-23

    原文格式PDF

  • 申请/专利权人 JN BIOSCIENCES LLC;

    申请/专利号EP20130825409

  • 发明设计人 TSURUSHITA NAOYA;TSO J. YUN;

    申请日2013-07-31

  • 分类号C07K16/18;A61K39/395;C07K16/28;C07K16/46;C07K19;

  • 国家 EP

  • 入库时间 2022-08-21 14:49:41

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号